Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.

Am J Cardiovasc Drugs

Department of Clinical Pharmacology, Ninewells Hospital, Dundee DD1 9SY, Scotland.

Published: October 2004

High uric acid levels are associated with increased morbidity and mortality rates in cardiovascular disease. In this article we explore the relationship between cardiovascular disease and xanthine oxidase activity. We look at the evidence that uric acid and its production via the xanthine oxidase pathway, may directly contribute to this increased cardiovascular risk. We examine the relationship between uric acid and other established cardiovascular risk factors and look at the evidence that reducing uric acid production may have a beneficial impact on cardiovascular morbidity and mortality. We conclude that although there is currently insufficient evidence to recommend the routine use of xanthine oxidase inhibitors in those with cardiovascular disease and asymptomatic hyperuricemia, there is sufficient evidence to warrant a large scale morbidity and mortality trial.

Download full-text PDF

Source
http://dx.doi.org/10.2165/00129784-200303050-00001DOI Listing

Publication Analysis

Top Keywords

cardiovascular disease
16
uric acid
16
morbidity mortality
12
xanthine oxidase
12
acid production
8
cardiovascular risk
8
cardiovascular
7
hyperuricemia adverse
4
adverse outcomes
4
outcomes cardiovascular
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!